Clinical Trials Logo

Clinical Trial Summary

In this prospective, observational, long term registry patients of all ages with a diagnosis of hypophosphatasia (HPP) are followed at participating sites in multiple countries.


Clinical Trial Description

The HPP Registry is an observational, prospective, long-term registry designed to collect data on HPP epidemiology, disease history, clinical course, symptoms and burden of disease from patients of all ages who have a diagnosis of HPP. Evaluation of safety and effectiveness data in patients with HPP who have/are receiving treatment with Asfotase alfa ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02306720
Study type Observational [Patient Registry]
Source Alexion Pharmaceuticals, Inc.
Contact
Status Enrolling by invitation
Phase
Start date April 2, 2017
Completion date December 31, 2031

See also
  Status Clinical Trial Phase
Completed NCT00952484 - Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP) Phase 2
Completed NCT00744042 - Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP) Phase 1/Phase 2
Active, not recruiting NCT04181164 - Evaluation of Bone Architecture and Bone Strength in Adults With Hypophosphatasia (HPP)
Completed NCT02104219 - Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)
Completed NCT01419028 - A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Completed NCT00739505 - Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP) Phase 1
Completed NCT01203826 - Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP) Phase 2